high-dose tetravalent dengue vaccine (HD-TDV) / Takeda - LARVOL DELTA

Serologic and antigenic response profiles following vaccination with the tetravalent dengue vaccine TAK-003 in a phase 2 randomized controlled study (ASTMH 2023) - P2 | "In a prespecified exploratory analysis, the study assessed dengue-specific immunoglobulin (Ig) G and Ig M antibody profiles, as well as the dengue non-structural protein 1 (NS1) antigen, in the serum of dengue-naive and dengue-exposed adults who received one dose of either the high-dose formulation (10-fold higher serotype-2 potency [HD-TDV]) or the approved formulation of TAK-003 (TDV)...Vaccine-induced Ig G and Ig M antibodies can impact serological confirmation of subsequent dengue infection in vaccinees, emphasizing the need for alternate, more sensitive antigen- and molecular-based assays for this purpose. NS1-based assays remain a useful tool for dengue diagnosis post vaccination."

Clinical • Late-breaking abstract • P2 data • Dengue Fever • Infectious Disease